Literature DB >> 15070689

Uninfected erythrocytes inhibit Plasmodium falciparum-induced cellular immune responses in whole-blood assays.

Siske S Struik1, Fakhreldin M Omer, Katerina Artavanis-Tsakonas, Eleanor M Riley.   

Abstract

Whole-blood assays (WBAs) have been successfully used as a simple tool for immuno-epidemiological field studies evaluating cellular immune responses to mycobacterial and viral antigens. Rather unexpectedly, we found very poor cytokine responses to malaria antigens in WBAs in 2 immuno-epidemiological studies carried out in malaria endemic populations in Africa. We have therefore conducted a detailed comparison of cellular immune responses to live (intact) and lysed malaria-infected erythrocytes in WBAs and in peripheral blood mononuclear cell (PBMC) cultures. We observed profound inhibition of both proliferative and interferon-gamma responses to malarial antigens in WBAs as compared with PBMC cultures. This inhibition was seen only for malaria antigens and could not be overcome by increasing either antigen concentration or responder cell numbers. Inhibition was mediated by intact erythrocytes and occurred early in the culture period, suggesting that failure of antigen uptake might underlie the lack of T-cell responses. In support of this hypothesis, we have shown that intact uninfected erythrocytes specifically inhibit phagocytosis of infected red blood cells by peripheral blood monocytes. We propose that specific biochemical interactions with uninfected erythrocytes inhibit the phagocytosis of malaria-infected erythrocytes and that this may impede T-cell recognition in vivo.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15070689     DOI: 10.1182/blood-2003-08-2867

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  Vitamin A supplementation increases ratios of proinflammatory to anti-inflammatory cytokine responses in pregnancy and lactation.

Authors:  S E Cox; P Arthur; B R Kirkwood; K Yeboah-Antwi; E M Riley
Journal:  Clin Exp Immunol       Date:  2006-06       Impact factor: 4.330

2.  Cellular tumor necrosis factor, gamma interferon, and interleukin-6 responses as correlates of immunity and risk of clinical Plasmodium falciparum malaria in children from Papua New Guinea.

Authors:  Leanne J Robinson; Marthe C D'Ombrain; Danielle I Stanisic; Jack Taraika; Nicholas Bernard; Jack S Richards; James G Beeson; Livingstone Tavul; Pascal Michon; Ivo Mueller; Louis Schofield
Journal:  Infect Immun       Date:  2009-04-20       Impact factor: 3.441

3.  Antibodies to variant surface antigens of Plasmodium falciparum-infected erythrocytes are associated with protection from treatment failure and the development of anemia in pregnancy.

Authors:  Gaoqian Feng; Elizabeth Aitken; Francisca Yosaatmadja; Linda Kalilani; Steven R Meshnick; Anthony Jaworowski; Julie A Simpson; Stephen J Rogerson
Journal:  J Infect Dis       Date:  2009-07-15       Impact factor: 5.226

4.  Strain variation in early innate cytokine induction by Plasmodium falciparum.

Authors:  R A Corrigan; J A Rowe
Journal:  Parasite Immunol       Date:  2010-07       Impact factor: 2.280

5.  Intermittent preventive treatment with sulfadoxine-pyrimethamine does not modify plasma cytokines and chemokines or intracellular cytokine responses to Plasmodium falciparum in Mozambican children.

Authors:  Diana Quelhas; Laura Puyol; Llorenç Quintó; Tacilta Nhampossa; Elisa Serra-Casas; Eusébio Macete; Pedro Aide; Sergi Sanz; John J Aponte; Denise L Doolan; Pedro L Alonso; Clara Menéndez; Carlota Dobaño
Journal:  BMC Immunol       Date:  2012-01-26       Impact factor: 3.615

6.  CD14(hi)CD16+ monocytes phagocytose antibody-opsonised Plasmodium falciparum infected erythrocytes more efficiently than other monocyte subsets, and require CD16 and complement to do so.

Authors:  Jingling Zhou; Gaoqian Feng; James Beeson; P Mark Hogarth; Stephen J Rogerson; Yan Yan; Anthony Jaworowski
Journal:  BMC Med       Date:  2015-07-07       Impact factor: 8.775

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.